Candel Therapeutics Stock Alpha and Beta Analysis
| CADL Stock | USD 4.51 0.06 1.31% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Candel Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Candel Therapeutics over a specified time horizon. Remember, high Candel Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Candel Therapeutics' market risk premium analysis include:
Beta 1.54 | Alpha (0.68) | Risk 4.62 | Sharpe Ratio (0.09) | Expected Return (0.42) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Candel |
Candel Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Candel Therapeutics market risk premium is the additional return an investor will receive from holding Candel Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Candel Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Candel Therapeutics' performance over market.| α | -0.68 | β | 1.54 |
Candel Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Candel Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Candel Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Candel Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Candel Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Candel Therapeutics shares will generate the highest return on investment. By understating and applying Candel Therapeutics stock market price indicators, traders can identify Candel Therapeutics position entry and exit signals to maximize returns.
Candel Therapeutics Return and Market Media
The median price of Candel Therapeutics for the period between Thu, Sep 5, 2024 and Wed, Dec 4, 2024 is 6.0 with a coefficient of variation of 17.76. The daily time series for the period is distributed with a sample standard deviation of 1.03, arithmetic mean of 5.82, and mean deviation of 0.87. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Manning Paul B of 14240 shares of Candel Therapeutics at 5.71 subject to Rule 16b-3 | 09/20/2024 |
2 | Acquisition by Aguilar-cordova Estuardo of 6214 shares of Candel Therapeutics at 7.0091 subject to Rule 16b-3 | 10/01/2024 |
3 | Disposition of 26988 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.92 subject to Rule 16b-3 | 10/02/2024 |
4 | Disposition of 1800 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.85 subject to Rule 16b-3 | 10/03/2024 |
5 | Disposition of 15000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.05 subject to Rule 16b-3 | 10/11/2024 |
6 | Disposition of 15000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.02 subject to Rule 16b-3 | 10/14/2024 |
7 | Disposition of 10412 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.03 subject to Rule 16b-3 | 10/15/2024 |
8 | Acquisition by Tak Paul Peter of 180108 shares of Candel Therapeutics subject to Rule 16b-3 | 10/18/2024 |
9 | Disposition of 12645 shares by Barone Francesca of Candel Therapeutics at 5.9734 subject to Rule 16b-3 | 10/22/2024 |
10 | Disposition of 1194 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.72 subject to Rule 16b-3 | 10/24/2024 |
11 | Disposition of 1597 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.8 subject to Rule 16b-3 | 10/25/2024 |
12 | Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference | 10/28/2024 |
13 | Disposition of 6000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.38 subject to Rule 16b-3 | 10/30/2024 |
14 | Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.3 subject to Rule 16b-3 | 10/31/2024 |
15 | Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.27 subject to Rule 16b-3 | 11/01/2024 |
16 | Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.33 subject to Rule 16b-3 | 11/06/2024 |
17 | Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.19 subject to Rule 16b-3 | 11/07/2024 |
18 | Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 4.92 subject to Rule 16b-3 | 11/08/2024 |
19 | Insiders Could Have Profited By Holding onto Candel Therapeutics Shares Despite 10 percent Drop | 11/12/2024 |
20 | Candel Therapeutics Inc Quarterly 10-Q Report - Quartzy | 11/15/2024 |
21 | Acquisition by Tak Paul Peter of 12900 shares of Candel Therapeutics at 1.55 subject to Rule 16b-3 | 11/21/2024 |
22 | Disposition of 20000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 4.97 subject to Rule 16b-3 | 11/25/2024 |
23 | Disposition of 22081 shares by Barone Francesca of Candel Therapeutics at 4.5556 subject to Rule 16b-3 | 11/29/2024 |
24 | Candel therapeutics CTO Tyagarajan Seshu sells 92,897 in stock | 12/03/2024 |
About Candel Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Candel or other stocks. Alpha measures the amount that position in Candel Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 15.84 | 12.81 | 2.59 | 2.46 | Net Debt To EBITDA | 3.22 | 2.73 | 0.34 | 0.32 |
Candel Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Candel Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Candel Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Candel Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Candel Therapeutics. Please utilize our Beneish M Score to check the likelihood of Candel Therapeutics' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Candel Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Candel Therapeutics Backtesting, Candel Therapeutics Valuation, Candel Therapeutics Correlation, Candel Therapeutics Hype Analysis, Candel Therapeutics Volatility, Candel Therapeutics History and analyze Candel Therapeutics Performance. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Candel Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.